Invus Global Management, Llc Purchases 1,538,462 Shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Director Invus Global Management, Llc bought 1,538,462 shares of the firm’s stock in a transaction that occurred on Monday, February 2nd. The shares were acquired at an average cost of $1.30 per share, for a total transaction of $2,000,000.60. Following the completion of the acquisition, the director directly owned 1,538,462 shares in the company, valued at $2,000,000.60. The trade was a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Lexicon Pharmaceuticals Trading Down 7.1%

Shares of Lexicon Pharmaceuticals stock opened at $1.18 on Friday. The company has a debt-to-equity ratio of 0.47, a current ratio of 5.64 and a quick ratio of 5.63. The business has a fifty day simple moving average of $1.30 and a two-hundred day simple moving average of $1.28. Lexicon Pharmaceuticals, Inc. has a 1 year low of $0.28 and a 1 year high of $1.83. The company has a market capitalization of $428.89 million, a price-to-earnings ratio of -6.21 and a beta of 0.98.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its quarterly earnings data on Thursday, November 6th. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.03. The firm had revenue of $14.18 million for the quarter, compared to the consensus estimate of $5.81 million. Lexicon Pharmaceuticals had a negative net margin of 96.77% and a negative return on equity of 52.90%. Research analysts forecast that Lexicon Pharmaceuticals, Inc. will post -0.66 EPS for the current year.

Analyst Ratings Changes

LXRX has been the topic of several research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lexicon Pharmaceuticals in a research report on Thursday, January 22nd. Wall Street Zen lowered Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, November 15th. Three equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $3.23.

Institutional Investors Weigh In On Lexicon Pharmaceuticals

Large investors have recently added to or reduced their stakes in the stock. Hudson Bay Capital Management LP acquired a new position in Lexicon Pharmaceuticals in the 2nd quarter valued at $26,000. R Squared Ltd acquired a new position in Lexicon Pharmaceuticals in the second quarter valued at about $28,000. Vermillion & White Wealth Management Group LLC lifted its position in Lexicon Pharmaceuticals by 400.0% during the third quarter. Vermillion & White Wealth Management Group LLC now owns 32,500 shares of the biopharmaceutical company’s stock worth $44,000 after purchasing an additional 26,000 shares during the period. Catalyst Funds Management Pty Ltd acquired a new stake in Lexicon Pharmaceuticals during the second quarter worth about $51,000. Finally, Bank of America Corp DE increased its holdings in Lexicon Pharmaceuticals by 80.1% in the 3rd quarter. Bank of America Corp DE now owns 57,804 shares of the biopharmaceutical company’s stock valued at $78,000 after buying an additional 25,707 shares during the period. Institutional investors and hedge funds own 74.70% of the company’s stock.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon’s approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.

The company’s most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.